Cover Image
Market Research Report
Product code 
229776

Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) - Drugs in Development, 2021

Published: | Global Markets Direct | 380 Pages | Delivery time: 1-2 business days

Price

Back to Top
Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) - Drugs in Development, 2021
Published: October 31, 2021
Global Markets Direct
Content info: 380 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents
  • List of Tables

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Respiratory Syncytial Virus Infections - Drugs In Development, 2021, provides an overview of the Respiratory Syncytial Virus Infections (Infectious Disease) pipeline landscape.Respiratory syncytial virus (RSV) infection is a respiratory disease. It infects the lungs and breathing passages. RSV commonly causes bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children less than one year of age. The symptoms of RSV infection include cough, stuffy or runny nose, mild sore throat, earache and fever. Treatment includes proper medication and hygiene practice.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Respiratory Syncytial Virus Infections - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Respiratory Syncytial Virus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Respiratory Syncytial Virus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Respiratory Syncytial Virus (RSV) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 10, 8, 12, 3, 70, 33 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 14, 11 and 8 molecules, respectively.

Respiratory Syncytial Virus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Respiratory Syncytial Virus Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Respiratory Syncytial Virus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Respiratory Syncytial Virus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Respiratory Syncytial Virus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Respiratory Syncytial Virus Infections (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Respiratory Syncytial Virus Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Respiratory Syncytial Virus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Product Code: GMDHC13109IDB

Table of Contents

Table of Contents

  • Introduction
  • Respiratory Syncytial Virus Infections - Overview
  • Respiratory Syncytial Virus Infections - Therapeutics Development
  • Respiratory Syncytial Virus Infections - Therapeutics Assessment
  • Respiratory Syncytial Virus Infections - Companies Involved in Therapeutics Development
  • Respiratory Syncytial Virus Infections - Drug Profiles
  • Respiratory Syncytial Virus Infections - Dormant Projects
  • Respiratory Syncytial Virus Infections - Discontinued Products
  • Respiratory Syncytial Virus Infections - Product Development Milestones
  • Appendix

List of Tables

List of Tables

  • Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Abhelix LLC, 2021
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Abivax SA, 2021
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by ADMA Biologics Inc, 2021
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Advac LLC, 2021
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Advagene Biopharma Co Ltd, 2021
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Advance Vaccine Laboratories Pty Ltd, 2021
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by AIM Vaccine Co Ltd, 2021
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Airway Therapeutics LLC, 2021
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by AlloVir Inc, 2021
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by AlphaVax Inc, 2021
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Anima Biotech Inc, 2021
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Aridis Pharmaceuticals Inc, 2021
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Artificial Cell Technologies Inc, 2021
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by AstraZeneca Plc, 2021
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Atea Pharmaceuticals Inc, 2021
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Atriva Therapeutics GmbH, 2021
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Auro Vaccines LLC, 2021
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by AVM Biotechnology LLC, 2021
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Bavarian Nordic A/S, 2021
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Beijing Advaccine Biotechnology Company Ltd, 2021
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by BioComo Inc, 2021
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Blue Lake Biotechnology Inc, 2021
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by BlueWillow Biologics Inc, 2021
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by BravoVax Co Ltd, 2021
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Calder Biosciences Inc, 2021
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Celestial Therapeutics Inc, 2021
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Changchun Bcht Biotechnology Co Ltd, 2021
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Chongqing Zhifei Biological Products Co Ltd, 2021
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Cidara Therapeutics Inc, 2021
  • Respiratory Syncytial Virus (RSV) Infections - Dormant Projects, 2021
  • Respiratory Syncytial Virus (RSV) Infections - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Top 10 Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021